Therapeutic Targets and Approaches to Manage Inflammation of NAFLD

Area of Science:

• Hepatology and Gastroenterology
• Immunology and Inflammation Research
• Metabolic and Cardiovascular Diseases

Background:

• Non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), represent a major global health burden.
• Inflammation is a key driver in the progression of NAFLD/NASH, contributing to liver damage and fibrosis.
• Current treatments for NAFLD/NASH, including lifestyle modification and existing drugs, show limited efficacy, especially in advanced disease stages.

Purpose of the Study:

• To review current therapeutic targets and strategies for managing inflammation in NAFLD/NASH.
• To explore emerging treatment approaches focusing on inflammation, metabolic dysfunction, and fibrosis.
• To emphasize the need for novel drug development and combination therapies for effective NAFLD/NASH management.

Main Methods:

• This review synthesizes current scientific literature on NAFLD/NASH pathogenesis and treatment.
• It analyzes emerging therapeutic strategies targeting key inflammatory pathways.
• The review discusses the challenges and future directions in clinical management.

Main Results:

• Inflammation is central to NAFLD/NASH progression, necessitating targeted therapies.
• Emerging strategies focus on modulating inflammation, metabolic pathways, and fibrotic processes.
• Despite promising avenues, challenges in treatment complexity and patient heterogeneity remain.

Conclusions:

• Effective management of NAFLD/NASH requires addressing underlying inflammation.
• Future therapeutic development should prioritize novel anti-inflammatory agents and combination therapies.
• Addressing the complexity and heterogeneity of NAFLD/NASH is crucial for improving patient outcomes.